Progressiveazotemia provoked by ACE inhibitor in renal ischemia


Cite item

Full Text

References

  1. Хирманов В. Н. Ишемическая болезнь почек. Тер. арх. 2001; 6: 61-61.
  2. Alcasar J. M., Rodicio J. L. Ischemic nephropathy: clinical characteristics and treatment. Am. J. Kidney Dis. 2000; 36: 883-893.
  3. Textor S. C, Wilcox С S. Ischemic nephropathy/azotemic renovascular disease. Semin. Nephrol. 2000; 20: 489-502.
  4. Мухин Н. А., Козловская Л. В., Кутырина И. М. и др. Ишемическая болезнь почек. Тер. арх. 2003; 6: 6-12.
  5. Grossman A., Eckland D., Price P., Edwards C. R. Captopril: reversible renal failure with severe hyperkalemia. Lancet 1980; 1: 712.
  6. Hricik D. E., Browning P. J., Kopelman R. et al. Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kid-ney. N. Engl. J. Med. 1983; 308: 373-376.
  7. Coulie P., De Plaen J. F., van Ypersele de Strihou С Captopril induced acute reversible renal failure. Nephron 1983; 35: 108- 111.
  8. Dominiczak A., Isles C, Gillen G., Brown J. J. Angiotensin converting enzyme inhibition and renal insufficiency in patients with bilateral renovascular disease. J. Hum. Hypertens. 1988; 2: 53-56.
  9. O'Donnell D. Renal failure due to enalapril and captopril in bilateral renal artery stenosis: greater awareness needed. Med. J. Aust. 1988; 148: 525-527.
  10. Hannedouche Т., Godin M., Fries D., Fillastre J. P. Acute renal thrombosis induced by angiotensin-converting enzyme inhibitors in patients with renovascular hypertension. Nephron 1991; 57: 230-231.
  11. Svarstad E., Willassen Y., Iversen В. М. Severe renal failure during treatment with angiotensin-converting enzyme inhibi tors. Tidsskr. Norske Laegeforen. 1992; 112: 463-465.
  12. Lakusic N., Mahovic D., Ciglenecki N. et al. Reversible impair ment of renal function during treatment with lisinopril, and ACE-inhibitor (case report). Lijec. Vjesn. 2001; 123: 245-248.
  13. Svarstad E., Hultstrom D., Jensen D. et al. Acute renal failure, renal artery stenosis and angiotensin-converting enzyme (ACE) inhibitor. Tidsskr. Norske Laegeforen. 2001; 121: 1784-1788.
  14. Silas J. H., Klenka Z., Solomon S. A., Bone J. M. Captopril induced reversible renal failure: a marker of renal artery stenosis affecting a solitary kidney. Br. Med. J. (Clin. Res. Ed.) 1983; 286: 1702-1703.
  15. Chabrier G., Simon С, Cherfan J. et al. Acute renal insufficiency induced by captopril disclosing renal artery stenosis in a solitary kidney. Rev. Med. Interne 1985; 6: 58-61.
  16. Lynggaard F., Jespersen С. M. Reversible renal failure due to captopril in a patient with renal artery stenosis in a solitary functioning kidney. Ugeskr. Laeg. 1985; 147: 1549-1550.
  17. Scanu P., Hurault de Ligny В., Ryckelynck J. P. Reversible acute renal insufficiency with combination of enalapril and diuretics in a patient with a single renal-artery stenosis. Nephron 1987; 45: 321-322.
  18. Mason J. C, Hilton P. J. Reversible renal failure due to captopril in a patient with transplant artery stenosis. Case report. Hypertension 1983; 5: 623-627.
  19. van Son W. J., van der Woude F. J., Tegzess A. M. Captoprilinduced deterioration of graft function in patients with a transplant renal artery stenosis. Proc. Eur. Dial. Transplant. Assoc. 1983; 20: 325-330.
  20. Tripathi K., Srivastava P. K., Tewari N. N, Mishra P. S. Reversible renal failure in autotransplanted restenosed bilateral renal artery stenosis with captopril. J. Assoc. Physicians India 1985; 33: 617.
  21. van de Ven P. J., Beutler J. J., Kaatee R. et al. Angiotensin converting enzyme inhibitor-induced renal dysfunction in atherosclerotic renovascular disease. Kidney Int. 1998; 53: 986-993.
  22. Wynckel A., Ebikili В., Melin J. P. et al. Long-term followup of acute renal failure caused by angiotensin converting enzyme inhibitors. Am. J. Hypertens. 1998; 11: 1080-1086.
  23. Devoy M. A., Tomson С R., Edmunds M. E. et al. Deterioration in renal function associated with angiotensin converting enzyme inhibitor therapy is not always reversible. J. Intern. Med. 1992; 232: 493-498.
  24. Adhiyaman V., Asghar M., Оке A. et al. Nephrotoxicity in the elderly due to coprescription of angiotensin-converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs. J. Roy. Soc. Med. 2001; 94: 512-514.
  25. Baraldi A., Ballestri M., Rapana R. et al. Acute renal failure of medical type in an elderly population. Nephrol. Dial. Transplant. 1998; 13 (suppl. 7): 25-29.
  26. Stirling C, Houston J., Robertson S. et al. Diarrhoea, vomiting and ACE inhibitors: an important cause of acute renal failure.J. Hum. Hypertens. 2003; 17: 419-423.
  27. Schepkens H., Vanholder R., Billiouw J. M., Lameire N. Lifethreatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: an analysis of 25 cases. Am. J. Med. 2001; 110: 438-441.
  28. Pedersen E. B. New tools in diagnosing renal artery stenosi Kidney Int. 2000; 57: 2657-2677.
  29. Alcasar J. M., Marin R., Gomez- Campdera F. et al. Clinic. characteristics of ischaemic renal disease. Nephrol. Dia Transplant. 2001; 16 (suppl. 1): 74-77.
  30. Staessen J. A., Gasowski J., Wang J. L. et al. Risks of untreate and treated isolated systolic hypertension in the elderly: meia analysis of outcome trials. Lancet 2000; 355: 865-872.
  31. Кобалава Ж. Д., Моисеев В. С. Систолическое давление ключевой показатель диагностики, контроля и прогнози рования риска артериальной гипертонии. Возможност блокады рецепторов ангиотензина II. Клин, фармакол.тер. 2000; 9: 86-95.
  32. Cirillo M., Stellate D., Laurenzi M. et al. Pulse pressure an isolated systolic hypertension: association with microalbuminu ria. The GUBBIO Study Collaborative Research Group. Kid ney Int. 2000; 58: 1211-1218.
  33. Ming J., Sheng L. L., Zhang L. G. et al. Abnormal renal func tion in isolated systolic hypertension correlation with ambula tory blood pressure. Int. J. Cardiol. 1993; 41: 69-75.
  34. Voyaki S. M., Staessen J. A., Thijs L. et al. Follow-up of rena function in treated and untreated older patients with isolatei systolic hypertension. Systolic Hypertension in Europe (Syst Eur) Trial Investigators. J. Hypertens. 2001; 19: 511-519.
  35. SHEP Cooperative Research Group. Prevention of stroke b; antihypertensive drug treatment in older persons with isolate< systolic hypertension. J. A. M. A. 1991; 265: 3255-3264.
  36. Forette F., Seux M. L., Staessen J. A. Prevention of dementi: in randomized doubleblind placebo-controlled systolic hyper tension in Europe (SYST-EUR) trial. Lancet 1998; 352 1347-1351.
  37. Brown M. J., Palmer С R., Castaigne A. et al. Influence of diabetes and type of hypertension on response to antihypertensivi treatment. Hypertension 2000; 35: 1038-1042.
  38. Zanchetti A., Bold G., Hennig M. et al. Calcium antagonist lac idipin slows down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Stud) on Atherosclerosis (ELSA), a randomized, double-blind, longterm trial. Circulation 2002; 106: 2422-2427.
  39. van Zweiten P. A. Drug treatment of isolated systolic hypertension. Nephrol. Dial. Transplant. 2001; 16: 1095-1097.
  40. Blanco-Colio L. M., Tunon J., Martin-Ventura J. L., Egido J Antiinflammatory and immunomodulatory effects of statins Kidney Int. 2003; 63: 12-23.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2004 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 

Address of the Editorial Office:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Correspondence address:

  • Alabyan Street, 13/1, Moscow, 127055, Russian Federation

Managing Editor:

  • Tel.: +7 (926) 905-41-26
  • E-mail: e.gorbacheva@ter-arkhiv.ru

 

 © 2018-2021 "Consilium Medicum" Publishing house


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies